Angiex

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Angiex sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Angiex: 1 sponsored US clinical trial, 1 recruiting.

Angiex sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced Carcinoma, with 1 trials.

Mid-pack sponsor footprint

Angiex is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 1

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06440005

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

Locally Advanced Carcinoma 1
Angiosarcoma 1
Liver Cancer 1
Metastatic Solid Tumor 1
Advanced Cancer 1
Pancreatic Cancer 1
Colorectal Cancer 1
Breast Cancer 1
Prostate Cancer 1
Cancer 1

What is open in the Angiex pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Locally Advanced Carcinoma (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Angiex: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Angiex sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Angiex1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Angiex sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Angiex sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Angiex page

1 registered trials is a research-attention snapshot, not an endorsement of Angiex or any single study.

  • 1 of Angiex's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Locally Advanced Carcinoma is the condition Angiex studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Angiex pipeline card: 1 registered trials from official public datasets.Report a data error.